• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    (CSE:BNXT)

    0.4700 UNCHANGED
    Streaming Delayed Price Updated: 3:59 PM EST, Jan 19, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about BNXT

    < Previous 1 2 3 Next >
    News headline image
    BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
    Via ACCESS Newswire
    News headline image
    Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
    Via ACCESS Newswire
    News headline image
    BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
    Via ACCESS Newswire
    News headline image
    BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
    Via ACCESS Newswire
    News headline image
    BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
    Via ACCESS Newswire
    News headline image
    BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
    VANCOUVER, BC / November 4, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF... 
    Via PressReach
    Topics Intellectual Property
    News headline image
    BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
    Via ACCESS Newswire
    News headline image
    BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization
    VANCOUVER, BC / October 30, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased... 
    Via PressReach
    Topics Intellectual Property
    News headline image
    BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
    Via ACCESS Newswire
    News headline image
    BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug
    BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead... 
    Via PressReach
    Topics Intellectual Property
    News headline image
    BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
    VANCOUVER, BC / October 21, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies,... 
    Via PressReach
    Topics Intellectual Property
    News headline image
    BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
    Via ACCESS Newswire
    News headline image
    BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
    Via ACCESS Newswire
    News headline image
    BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
    Via ACCESS Newswire
    News headline image
    BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
    Via ACCESS Newswire
    News headline image
    Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
    Via ACCESS Newswire
    News headline image
    BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development
    Via ACCESS Newswire
    News headline image
    BioNxt Solutions Completes Up-Listing to The OTCQB Market
    Via ACCESS Newswire
    News headline image
    Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
    Via ACCESS Newswire
    News headline image
    BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
    Via ACCESS Newswire
    News headline image
    BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
    Via ACCESS Newswire
    News headline image
    BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation
    Via ACCESS Newswire
    News headline image
    BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology
    Via ACCESS Newswire
    News headline image
    BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
    Via ACCESS Newswire
    News headline image
    BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets
    Via ACCESS Newswire
    News headline image
    BioNxt Solutions Provides Bi-weekly MCTO Status Report
    Via ACCESS Newswire
    News headline image
    BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent
    Via ACCESS Newswire
    News headline image
    BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory
    Via ACCESS Newswire
    News headline image
    BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization
    Via ACCESS Newswire
    News headline image
    BioNxt Solutions Prepares for Human Bioequivalence Study For MS
    Via ACCESS Newswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.